Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cabozantinib and Nivolumab in Older Patients with Renal Cell Carcinoma
NCT06934057Phase 4
Key facts
- Status
- Recruiting
- Start
- May 2025
- Primary completion
- Apr 2028
- Countries
- 1
- Sponsor
- Gustave Roussy
- Modality
- Small Molecules
- Drugs
- cabozantinib
- Conditions
- renal cell carcinoma (RCC)
01
Overview
Phase 4, open-label, single-arm trial of cabozantinib in renal cell carcinoma (RCC), sponsored by Gustave Roussy. Primary endpoints: Starting dose of Cabozantinib at 24 weeks, Dose interruption of Cabozantinib at 24 weeks and 1 more. Started May 2025; status: recruiting.
02
Design
1 arm- Study design
- Non-randomizedOpen-label
Cabozantinib-Nivolumab
Standard of care Nivolumab + Cabozantinib with geriatric evaluation.
03
Who it enrols
Patients aged 70 or older with confirmed advanced or metastatic renal-cell carcinoma who have not been previously treated in the metastatic setting.
04
Endpoints
Primary
Starting dose of Cabozantinib
Dose interruption of Cabozantinib
Dose modifications of Cabozantinib
Secondary
Overall Response Rate
Overall Survival
Progression-Free Survival
Duration of Response
Frequency of adverse events according to CTCAE V5
Frequency of adverse events according to PRO-CTCAE
Quality of Life - FACT-G
Quality of Life - FACIT TS-G
Beyond the preview
Go deeper on NCT06934057.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06934057.